# Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins

Study · id `cardio:ct-nct06262685` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06262685](<https://clinicaltrials.gov/study/NCT06262685>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06262685

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 216 participants.

## Technical summary

Registry record NCT06262685. Randomized; single masking; primary purpose treatment. Start 2024-03-04 (anticipated); primary completion 2025-02-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 216 participants (planned count; ClinicalTrials.gov record NCT06262685, source copy `cardio:ctgov-nct06262685-2024-02-16`, retrieved 2026-10-31)
- Planned start: 2024-03-04 (anticipated) (ClinicalTrials.gov record NCT06262685, source copy `cardio:ctgov-nct06262685-2024-02-16`, retrieved 2026-10-31)
- Primary completion: 2025-02-10 (anticipated) (ClinicalTrials.gov record NCT06262685, source copy `cardio:ctgov-nct06262685-2024-02-16`, retrieved 2026-10-31)
- Completion: 2025-03-04 (anticipated) (ClinicalTrials.gov record NCT06262685, source copy `cardio:ctgov-nct06262685-2024-02-16`, retrieved 2026-10-31)
- Countries: Spain (ClinicalTrials.gov record NCT06262685, source copy `cardio:ctgov-nct06262685-2024-02-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06262685-2024-02-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins
- Acronym: PREVESTATGx
- Condition: Cardiovascular Diseases
- Condition: Dyslipidemias
- Condition: Statin Adverse Reaction
- Condition: Pharmacogenic Myopathy
- Intervention (Other): Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines
- Intervention (Other): Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines
- Intervention (Other): Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines
- Intervention (Other): Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines
- Intervention (Other): Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines
- Intervention (Other): Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines
- Intervention (Other): Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines
- Intervention (Other): Standard of Care (SoC) dosing of atorvastatin
- Intervention (Other): Standard of Care (SoC) dosing of simvastatin
- Intervention (Other): Standard of Care (SoC) dosing of pitavastatin
- Intervention (Other): Standard of Care (SoC) dosing of rosuvastatin
- Intervention (Other): Standard of Care (SoC) dosing of prasavastatin
- Intervention (Other): Standard of Care (SoC) dosing of lovastatin
- Intervention (Other): Standard of Care (SoC) dosing of fluvastatin
- Lead sponsor: Instituto de Investigación Hospital Universitario La Paz
- Lead sponsor class: OTHER
- Collaborator: Instituto de Salud Carlos III
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Instituto de Investigación Hospital Universitario La Paz (`cardio:org-instituto-de-investigacion-hospital-universitario-la-paz`)
- Registry lists this organization as a collaborator: Instituto de Salud Carlos III (`cardio:org-instituto-de-salud-carlos-iii`)

## Provenance

Content hash: bfed0fb2a371a4f6929a9d056d93d77371c3970efb543e43982b9e80c6495c04
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
